|
CHD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.48020048942976E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.4377999618963E-09 |
| Normal-vs-Stage2 |
6.57370002876689E-09 |
| Normal-vs-Stage3 |
1.45528034067866E-12 |
| Normal-vs-Stage4 |
1.76250125605293E-11 |
| Stage1-vs-Stage2 |
2.670200E-01 |
| Stage1-vs-Stage3 |
1.117420E-01 |
| Stage1-vs-Stage4 |
1.951710E-02 |
| Stage2-vs-Stage3 |
9.488600E-01 |
| Stage2-vs-Stage4 |
5.495200E-01 |
| Stage3-vs-Stage4 |
5.108400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.91339960437165E-10 |
| Normal-vs-AfricanAmerican |
3.084500E-03 |
| Normal-vs-Asian |
7.89340000029171E-08 |
| Caucasian-vs-AfricanAmerican |
7.459600E-02 |
| Caucasian-vs-Asian |
7.097200E-01 |
| AfricanAmerican-vs-Asian |
2.074000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.86950019301457E-10 |
| Normal-vs-Female |
1.62669877568078E-12 |
| Male-vs-Female |
6.707000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.9329999519141E-09 |
| Normal-vs-Age(41-60Yrs) |
1.45472522916634E-12 |
| Normal-vs-Age(61-80Yrs) |
8.43947134399059E-12 |
| Normal-vs-Age(81-100Yrs) |
7.990000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.159400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.081200E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.370600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.071600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.320200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.727000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.218030E-04 |
| Classical-VS-Follicular |
8.37170000000942E-05 |
| Classical-VS-Other |
2.545400E-01 |
| Classical-VS-Normal |
5.61230000251101E-08 |
| Tall-VS-Follicular |
6.413800E-01 |
| Tall-VS-Other |
6.060200E-01 |
| Tall-VS-Normal |
9.83402248522225E-12 |
| Follicular-VS-Other |
8.549800E-01 |
| Follicular-VS-Normal |
1.80866432941684E-12 |
| Other-VS-Normal |
2.259000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.50199885651637E-11 |
| Normal-vs-N1 |
1.12650000438919E-08 |
| N0-vs-N1 |
9.192600E-01 |
|
|
